Oncolytics Biotech Inc. to Present at BioSquare 2008

CALGARY, AB, --- March 10, 2008--- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the BioSquare 2008 Conference on Thursday, March 13, 2008. The event is being held at the Congress Center in Basel, Switzerland from March 12-14, 2008.

For more information on BioSquare go here.

Update on Kenny

Check out Deborah Foster's "When the Family has Cancer" page for an update on Kenny, a patient in Oncolytics Biotech's phase II program.

Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007

CALGARY, AB, March 6, 2008 --- Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) (“Oncolytics” or the “Company”) today reported its financial results for the year ended December 31, 2007.

“2007 was our most productive year to date, marking a significant expansion of the Company’s clinical trial program for REOLYSIN® with Phase II studies and combination drug therapy studies being expanded and initiated,” said Dr. Brad Thompson, President and CEO of Oncolytics. “This activity was supported by further advances in our preclinical development program, manufacturing, and intellectual property.”

Selected Highlights:

Clinical Trial Results Presented

• Final results from our Phase I U.K. systemic administration trial, and our U.S. Phase I systemic administration trial at ASCO;
• Positive interim results from our U.K. Phase Ia/Ib combination REOLYSIN® and radiation trial;

Clinical Trial Progress

• Commenced patient enrolment in three combination REOLYSIN® and chemotherapy trials in the U.K.;
• Commenced patient enrolment in a U.S. Phase II trial for patients with various sarcomas that have metastasized to the lung;
• U.S. National Cancer Institute (NCI) filed a protocol with the U.S. Food and Drug Administration (FDA) to conduct a Phase II melanoma trial with REOLYSIN®;
• Approval to begin a Phase I combination REOLYSIN® and cyclophosphamide trial in the U.K.;
• In January 2008, the NCI filed a protocol with the U.S. FDA to conduct a Phase I/II ovarian, peritoneal and fallopian tube cancer trial;
• In January 2008, met the criteria to expand to full enrolment of 52 patients in our U.S. Phase II sarcoma trial;

Manufacturing

• Completed scale up of our manufacturing process to the 40-litre level and investigated further increases in scale to the 100-litre level;

Financial and Intellectual Property

• Completed a public offering that added gross proceeds of $13.8 million to our financial reserves; and,
• Secured an additional eight U.S, patents and one Canadian patent, bringing our current total to more than 165 patents issued worldwide;

“We expect 2008 to be an outstanding year as we move ahead with our Phase II program and begin to focus our efforts in the clinical program in key indications,” said Thompson. “With solid preclinical and Phase I results, a scalable manufacturing process, a comprehensive intellectual property portfolio and the financial resources to support our Phase II program, we are well positioned for an exciting and productive 2008.”

View the complete report here.

Oncolytics Biotech Inc. to Present at Oncology Biologics Development Primer

CALGARY, Alberta, --- February 21, 2008 – Dr. Matt Coffey, Chief Scientific Officer of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate as an invited speaker in a session entitled “Case Studies in Gene Therapies” at the Oncology Biologics Development Primer (OBDP) conference on Friday, February 29, 2008. The OBDP was developed by the International Society for Biological Therapy of Cancer (iSBTc) to explore and discuss best practices for worldwide biologics development. The conference runs from February 28-29, 2008 in Gaithersburg, MD.

For more information about the conference, please visit www.isbtc.org and click on “Oncology Biologics Development Primer.”

Virus as Viable Drug

"Coincidence or phenomena? The reovirus is Mother Nature's own cancer-killer." Provocative headlines from PharmExec.com.

Read the full article here.

Latest update on Kenny

Kenny, a patient in the San Antonio trials, checks in with some new information:

...this last time, I also had a PET scan (my first one). The results showed “no metabolic activity”, which “suggests” that there may not be any active cancer cells anywhere. Medically speaking, there seems to be little evidence that I have cancer any more...

Exciting indeed. I encourage everyone to keep Kenny in your prayers.

Read the full article here.

Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference

CALGARY, Alberta, --- February 6, 2008

Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate as an invited speaker as part of a panel discussion entitled “Breaking Down the Barriers to New Neuro-Oncology Drugs” at the 10th Annual Bio CEO & Investor Conference 2008 on Monday, February 11 at 9:30 a.m. (ET). The conference, which is expected to draw more than 1,000 biotechnology and life sciences investors, will be held at the Waldorf-Astoria Hotel in New York City on February 11-13, 2008.